pubmed-article:2021932 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:2021932 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
pubmed-article:2021932 | lifeskim:mentions | umls-concept:C0014264 | lld:lifeskim |
pubmed-article:2021932 | lifeskim:mentions | umls-concept:C0315417 | lld:lifeskim |
pubmed-article:2021932 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
pubmed-article:2021932 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
pubmed-article:2021932 | pubmed:issue | 10 | lld:pubmed |
pubmed-article:2021932 | pubmed:dateCreated | 1991-6-3 | lld:pubmed |
pubmed-article:2021932 | pubmed:abstractText | We report a phase I study in cancer patients being treated with i.v. bolus injections of highly purified lipopolysaccharide (LPS) Salmonella abortus equi. Twenty-four patients with disseminated cancer received escalating doses of LPS at 2-week intervals. Dose escalation was performed in six dose levels treating 3-6 patients at each level. Dose levels 1 and 2 consisted of 0.15 and 0.3 ng/kg, respectively. Further dose escalation up to 5.0 ng/kg was enabled by pretreatment with ibuprofen, which attenuated the constitutional side effects of LPS. The maximum tolerated dose was 4.0 ng/kg with dose-limiting toxicity being World Health Organization grade III hepatic toxicity. Hematological changes included transient decreases in WBCs affecting granulocytes, monocytes, and lymphocytes in a marked different pattern. Endogenous cytokine release occurred in an LPS dose-dependent manner as measured by tumor necrosis factor-alpha, interleukin-6, and macrophage colony-stimulating factor serum levels. Moderate antitumor activity in colorectal cancer was observed in the case of 2 patients. Phase II trials of LPS are currently in progress. | lld:pubmed |
pubmed-article:2021932 | pubmed:language | eng | lld:pubmed |
pubmed-article:2021932 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:2021932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:2021932 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:2021932 | pubmed:month | May | lld:pubmed |
pubmed-article:2021932 | pubmed:issn | 0008-5472 | lld:pubmed |
pubmed-article:2021932 | pubmed:author | pubmed-author:GalanosCC | lld:pubmed |
pubmed-article:2021932 | pubmed:author | pubmed-author:EngelhardtRR | lld:pubmed |
pubmed-article:2021932 | pubmed:author | pubmed-author:MackensenAA | lld:pubmed |
pubmed-article:2021932 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:2021932 | pubmed:day | 15 | lld:pubmed |
pubmed-article:2021932 | pubmed:volume | 51 | lld:pubmed |
pubmed-article:2021932 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:2021932 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:2021932 | pubmed:pagination | 2524-30 | lld:pubmed |
pubmed-article:2021932 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:meshHeading | pubmed-meshheading:2021932-... | lld:pubmed |
pubmed-article:2021932 | pubmed:year | 1991 | lld:pubmed |
pubmed-article:2021932 | pubmed:articleTitle | Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. | lld:pubmed |
pubmed-article:2021932 | pubmed:affiliation | Medizinische Klinik I, Albert-Ludwigs-Universität, Freiburg, Federal Republic of Germany. | lld:pubmed |
pubmed-article:2021932 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:2021932 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:2021932 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2021932 | lld:pubmed |